Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment recommendations for lupus nephritis.

C Ponticelli1

  • 1Divisione di Nefrologia e Dialisi, Istituto Scientifico Ospedale Maggiore, Milano, Italy.

Drugs
|July 1, 1990
PubMed
Summary

Systemic lupus erythematosus often affects the kidneys, requiring careful monitoring. Early, vigorous treatment of lupus nephritis with corticosteroids and cytotoxic agents can improve long-term patient and kidney survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should we really STOP treating patients with IgA nephropathy with steroids?

Physiology international·2018
Same author

Synthetic pharmacotherapy for lupus nephritis.

Expert opinion on pharmacotherapy·2017
Same author

Hydroxychloroquine in systemic lupus erythematosus (SLE).

Expert opinion on drug safety·2016
Same author

A randomized trial of everolimus and low-dose cyclosporine in renal transplantation: with or without steroids?

Transplantation proceedings·2014
Same author

Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years.

Lupus·2013
Same author

Present and future of immunosuppressive therapy in kidney transplantation.

Transplantation proceedings·2011

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Background:

  • Renal disease is a frequent complication of systemic lupus erythematosus (SLE).
  • The course of lupus nephritis is highly variable, ranging from mild involvement to severe, active disease.
  • Early recognition and intervention are crucial for managing lupus nephritis.

Purpose of the Study:

  • To outline current therapeutic strategies for lupus nephritis.
  • To emphasize the importance of tailored treatment based on disease severity.
  • To discuss the role of corticosteroids and cytotoxic agents in managing lupus nephritis.

Main Methods:

  • Review of established treatment protocols for lupus nephritis.
  • Emphasis on the use of corticosteroids (e.g., methylprednisolone, prednisone) as a primary therapy.
  • Consideration of cytotoxic agents (e.g., cyclophosphamide) for refractory cases.
  • Discussion of minimizing corticosteroid toxicity through dosage adjustments and alternate-day regimens.

Main Results:

  • Corticosteroids are the cornerstone of lupus nephritis treatment.
  • High-dose intravenous methylprednisolone followed by oral prednisone can effectively reverse disease flares.
  • Reducing steroid dosage to the lowest effective level and considering alternate-day regimens helps minimize toxicity.
  • Cytotoxic agents may be necessary for patients with persistent disease activity.

Conclusions:

  • Optimized use of corticosteroids and cytotoxic agents, coupled with vigilant patient monitoring, can lead to excellent long-term survival rates for patients with lupus nephritis.
  • While optimal treatment is still evolving, current strategies offer significant benefits.
  • Further research into novel therapies like cyclosporine and lymphoid irradiation is ongoing.

Related Experiment Videos